Ariad Pharmaceuticals (ARIA) 7.20 $ARIA
Uptrend Call Working As Ariad Pharmaceuticals Stock Rises 20.9% (ARIA)
Comtex SmarTrend(R) - Tue Dec 02, 11:13AM CST
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on October 29th, 2014 at $5.92. In approximately 1 month, Ariad Pharmaceuticals has returned 20.88% as of today's recent price of $7.15.
ARIA: 7.20 (-0.26)
ARIAD Pharmaceuticals (ARIA) Is Strong On High Volume Today
at The Street - Tue Dec 02, 9:00AM CST
Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a strong on high relative volume candidate
ARIA: 7.20 (-0.26)
Vargatef cleared in Europe for lung cancer
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 8:23AM CST
HTBX: 4.40 (-0.20), BIB: 128.92 (-1.83), INCY: 74.12 (-0.54), PFE: 31.67 (-0.08), IBB: 306.20 (-2.05), DRGS: 54.00 (unch), BIND: 6.14 (-0.58), BMY: 58.89 (-0.14), GSK: 45.89 (-0.82), ONTY: 1.73 (+0.05), ECYT: 6.16 (-0.19), BIS: 46.40 (+0.64), CLVS: 48.63 (-0.15), AZN: 73.94 (+0.12), MRK: 60.92 (+0.34), ARIA: 7.20 (-0.26), IRY: 49.05 (+0.06), IXJ: 103.43 (-0.03), FPRX: 20.65 (-0.25)
Most active Nasdaq-traded stocks
AP - Tue Nov 25, 5:58PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
MU: 36.07 (-0.03), GILD: 101.82 (+0.94), FB: 75.24 (+0.36), CMCSK: 56.28 (-0.70), ARIA: 7.20 (-0.26), ARCP: 9.18 (-0.11), MSFT: 48.84 (+0.76), INTC: 37.46 (+0.03), CMCSA: 56.37 (-0.77), AAPL: 115.49 (-0.44), CSCO: 27.77 (-0.18)
Ariad Pharmaceuticals (ARIA) Jumps: Stock Gains 9.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 25, 8:25AM CST
Ariad Pharmaceuticals (ARIA) was a big mover last session, as the company saw its shares rise nearly 10% on the day.
LCI: 47.49 (-0.60), VRX: 144.33 (-0.94), SCMP: 13.57 (+0.36), ARIA: 7.20 (-0.26)
Insider Trading Alerts for Hertz, Ariad Pharmaceuticals, J C Penney, Sirius XM, Apple, and Sunedison
PR Newswire - Tue Nov 25, 7:45AM CST
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Hertz (NYSE:HTZ), Ariad Pharmaceuticals (NASDAQ:ARIA), J C Penney (NYSE:JCP), Sirius XM (NASDAQ:SIRI), Apple (NASDAQ:AAPL), and Sunedison (NYSE:SUNE).
HTZ: 24.25 (+0.10), SUNE: 20.85 (-0.40), JCP: 6.73 (-0.46), ARIA: 7.20 (-0.26), AAPL: 115.49 (-0.44), SIRI: 3.58 (-0.02)
Ariad Pharmaceuticals Rises 9.59% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Nov 24, 4:56PM CST
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $6.74 to a high of $7.24. Yesterday, the shares gained 9.6%, which took the trading range above the 3-day high of $6.84 on volume of 16.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ARIA: 7.20 (-0.26)
Iclusig cleared in Australia
Seeking Alpha - at Seeking Alpha - Mon Nov 24, 9:41AM CST
ARIA: 7.20 (-0.26)
ARIAD Pharmaceuticals (ARIA) Strong On High Relative Volume Today
at The Street - Mon Nov 24, 9:04AM CST
Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a strong on high relative volume candidate
ARIA: 7.20 (-0.26)
Earnings Look Back: Ariad Pharmaceuticals Is Up 14.6% Since Reporting Quarterly Results 2 Weeks Ago (ARIA)
Comtex SmarTrend(R) - Mon Nov 24, 8:34AM CST
19 days ago, on November 5th, 2014, Ariad Pharmaceuticals (NASDAQ:ARIA) reported its earnings. Analysts, on average, expected a loss of $0.29 per share on sales of $16.4 million. Ariad Pharmaceuticals actually reported a loss of $0.27 per share on sales of $14.7 million, beating EPS estimates by $0.02 and missing revenue estimates by $1.7 million. Since the company's report, shares of Ariad Pharmaceuticals have risen from $5.69 to $6.52, representing a gain of 14.6% in the past 19 days.
ARIA: 7.20 (-0.26)
ARIAD and STA Announce Approval of Iclusig (Ponatinib) in Australia
Business Wire - Mon Nov 24, 6:35AM CST
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) and Specialised Therapeutics Australia Pty Ltd (STA), today announced the marketing approval of Iclusig(TM)(ponatinib) in Australia by the Therapeutic Goods Administration (TGA).
ARIA: 7.20 (-0.26)
Ariad Pharmaceuticals Earnings Review: 12 Days after Announcement Shares Up 8.1% (ARIA)
Comtex SmarTrend(R) - Mon Nov 17, 2:37PM CST
A week ago on November 5th, 2014 Ariad Pharmaceuticals (NASDAQ:ARIA) reported earnings and analysts, on average, expected a loss of $0.29 on sales of $16.4 million. The company actually reported a loss of $0.27 per share on sales of $14.7 million, beating EPS estimates by $0.02 and missing revenue estimates by $1.7 million. Since the company's report, shares of Ariad Pharmaceuticals have risen from $5.69 to $6.15, representing a gain of 8.1% in the past 12 days.
ARIA: 7.20 (-0.26)
Equity Coverage on Biotech Industry - Gilead Sciences, MannKind, ARIAD Pharma, iBio Inc., and Celgene
PR Newswire - Fri Nov 14, 8:10AM CST
Investor-Edge has initiated coverage on the following equities: Gilead Sciences Inc. (NASDAQ: GILD), MannKind Corporation (NASDAQ: MNKD), ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), iBio Inc. (NYSE MKT: IBIO), and Celgene Corporation (NASDAQ: CELG). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Thursday, November 13, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,652.79, up 0.23% and the NASDAQ Composite closed at 4,680.14, up 0.11%. The S&P 500 finished the session 0.05% higher at 2,039.33. During the trading session, four out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 783.78, down 0.10%, whereas the index has gained 10.85% in the previous three months. Register for your complimentary reports on these five stocks at:
GILD: 101.82 (+0.94), IBIO: 0.77 (-0.13), ARIA: 7.20 (-0.26), MNKD: 5.41 (-0.29), CELG: 113.63 (-0.60)
'Mad Money' Lightning Round: A Group to Avoid
at The Street - Fri Nov 14, 5:00AM CST
Cramer says he's not going against Affymetrix, and doesn't want to get back into the sand game.
DCT: 34.46 (+0.46), CBI: 46.07 (-1.33), FMSA: 8.03 (-0.64), KODK: 21.30 (+0.10), WNR: 42.58 (-0.67), FRT: 132.81 (+0.13), ARIA: 7.20 (-0.26), AFFX: 9.14 (-0.04), ADSK: 61.09 (-0.36)
Cramer's Lightning Round - Affymetrix Teased And Disappointed, But Is A Buy (11/13/14)
SA Editor Miriam Metzinger - Seeking Alpha - Fri Nov 14, 2:40AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday November 13. Bullish Calls: Affymetrix (NASDAQ: AFFX ): "This company has over time teased people and then disappointed them, but I believe...
CBI: 46.07 (-1.33), FMSA: 8.03 (-0.64), KODK: 21.30 (+0.10), WNR: 42.58 (-0.67), FRT: 132.81 (+0.13), ARIA: 7.20 (-0.26), ADSK: 61.09 (-0.36), AFFX: 9.14 (-0.04)
Jim Cramer's 'Mad Money' Recap: Market 'Losers' Back in the Game
at The Street - Thu Nov 13, 5:49PM CST
Some stocks written off by this market are looking better than ever, Cramer says.
FLEX: 11.27 (+0.03), KMB: 114.60 (-0.10), M: 62.50 (-1.16), WMT: 84.76 (-0.18), FLTX: 34.30 (-0.17), AFFX: 9.14 (-0.04), DPS: 72.12 (-0.28), DCT: 34.46 (+0.46), JACK: 75.87 (+0.42), FMSA: 8.03 (-0.64), CSCO: 27.77 (-0.18), CBI: 46.07 (-1.33), KODK: 21.30 (+0.10), DIS: 93.23 (+0.12), WNR: 42.58 (-0.67), FRT: 132.81 (+0.13), BA: 131.32 (-0.65), PLKI: 54.22 (-0.47), AZO: 588.07 (-2.48), JCP: 6.73 (-0.46), JWN: 75.70 (-0.63), ARIA: 7.20 (-0.26), DOW: 49.77 (+0.35), ADSK: 61.09 (-0.36)
ARIAD Announces Iclusig Data Presentations at Annual American Society of Hematology Meeting
Business Wire - Thu Nov 06, 8:44AM CST
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced the schedule of several data presentations on Iclusig(R) (ponatinib) that will take place at the 56th Annual Meeting of the American Society of Hematology (ASH) being held in San Francisco, December 6 to 9, 2014. A total of 17 abstracts were accepted at ASH. The schedule and meeting location for key sessions at ASH, together with the abstract information, are listed below:
ARIA: 7.20 (-0.26)
Ariad Pharmaceuticals' (ARIA) CEO Harvey Berger on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 05, 11:47AM CST
ARIA: 7.20 (-0.26)
Uptrend Call Working As Ariad Pharmaceuticals Stock Rises 20.9% (ARIA)
Comtex SmarTrend(R) - Tue Dec 02, 11:13AM CST
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on October 29th, 2014 at $5.92. In approximately 1 month, Ariad Pharmaceuticals has returned 20.88% as of today's recent price of $7.15.
ARIA: 7.20 (-0.26)
ARIAD Pharmaceuticals (ARIA) Is Strong On High Volume Today
at The Street - Tue Dec 02, 9:00AM CST
Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a strong on high relative volume candidate
ARIA: 7.20 (-0.26)
Vargatef cleared in Europe for lung cancer
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 8:23AM CST
HTBX: 4.40 (-0.20), BIB: 128.92 (-1.83), INCY: 74.12 (-0.54), PFE: 31.67 (-0.08), IBB: 306.20 (-2.05), DRGS: 54.00 (unch), BIND: 6.14 (-0.58), BMY: 58.89 (-0.14), GSK: 45.89 (-0.82), ONTY: 1.73 (+0.05), ECYT: 6.16 (-0.19), BIS: 46.40 (+0.64), CLVS: 48.63 (-0.15), AZN: 73.94 (+0.12), MRK: 60.92 (+0.34), ARIA: 7.20 (-0.26), IRY: 49.05 (+0.06), IXJ: 103.43 (-0.03), FPRX: 20.65 (-0.25)
Most active Nasdaq-traded stocks
AP - Tue Nov 25, 5:58PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
MU: 36.07 (-0.03), GILD: 101.82 (+0.94), FB: 75.24 (+0.36), CMCSK: 56.28 (-0.70), ARIA: 7.20 (-0.26), ARCP: 9.18 (-0.11), MSFT: 48.84 (+0.76), INTC: 37.46 (+0.03), CMCSA: 56.37 (-0.77), AAPL: 115.49 (-0.44), CSCO: 27.77 (-0.18)
Ariad Pharmaceuticals (ARIA) Jumps: Stock Gains 9.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 25, 8:25AM CST
Ariad Pharmaceuticals (ARIA) was a big mover last session, as the company saw its shares rise nearly 10% on the day.
LCI: 47.49 (-0.60), VRX: 144.33 (-0.94), SCMP: 13.57 (+0.36), ARIA: 7.20 (-0.26)
Insider Trading Alerts for Hertz, Ariad Pharmaceuticals, J C Penney, Sirius XM, Apple, and Sunedison
PR Newswire - Tue Nov 25, 7:45AM CST
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Hertz (NYSE:HTZ), Ariad Pharmaceuticals (NASDAQ:ARIA), J C Penney (NYSE:JCP), Sirius XM (NASDAQ:SIRI), Apple (NASDAQ:AAPL), and Sunedison (NYSE:SUNE).
HTZ: 24.25 (+0.10), SUNE: 20.85 (-0.40), JCP: 6.73 (-0.46), ARIA: 7.20 (-0.26), AAPL: 115.49 (-0.44), SIRI: 3.58 (-0.02)
Ariad Pharmaceuticals Rises 9.59% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Nov 24, 4:56PM CST
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $6.74 to a high of $7.24. Yesterday, the shares gained 9.6%, which took the trading range above the 3-day high of $6.84 on volume of 16.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ARIA: 7.20 (-0.26)
Iclusig cleared in Australia
Seeking Alpha - at Seeking Alpha - Mon Nov 24, 9:41AM CST
ARIA: 7.20 (-0.26)
ARIAD Pharmaceuticals (ARIA) Strong On High Relative Volume Today
at The Street - Mon Nov 24, 9:04AM CST
Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a strong on high relative volume candidate
ARIA: 7.20 (-0.26)
Earnings Look Back: Ariad Pharmaceuticals Is Up 14.6% Since Reporting Quarterly Results 2 Weeks Ago (ARIA)
Comtex SmarTrend(R) - Mon Nov 24, 8:34AM CST
19 days ago, on November 5th, 2014, Ariad Pharmaceuticals (NASDAQ:ARIA) reported its earnings. Analysts, on average, expected a loss of $0.29 per share on sales of $16.4 million. Ariad Pharmaceuticals actually reported a loss of $0.27 per share on sales of $14.7 million, beating EPS estimates by $0.02 and missing revenue estimates by $1.7 million. Since the company's report, shares of Ariad Pharmaceuticals have risen from $5.69 to $6.52, representing a gain of 14.6% in the past 19 days.
ARIA: 7.20 (-0.26)
ARIAD and STA Announce Approval of Iclusig (Ponatinib) in Australia
Business Wire - Mon Nov 24, 6:35AM CST
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) and Specialised Therapeutics Australia Pty Ltd (STA), today announced the marketing approval of Iclusig(TM)(ponatinib) in Australia by the Therapeutic Goods Administration (TGA).
ARIA: 7.20 (-0.26)
Ariad Pharmaceuticals Earnings Review: 12 Days after Announcement Shares Up 8.1% (ARIA)
Comtex SmarTrend(R) - Mon Nov 17, 2:37PM CST
A week ago on November 5th, 2014 Ariad Pharmaceuticals (NASDAQ:ARIA) reported earnings and analysts, on average, expected a loss of $0.29 on sales of $16.4 million. The company actually reported a loss of $0.27 per share on sales of $14.7 million, beating EPS estimates by $0.02 and missing revenue estimates by $1.7 million. Since the company's report, shares of Ariad Pharmaceuticals have risen from $5.69 to $6.15, representing a gain of 8.1% in the past 12 days.
ARIA: 7.20 (-0.26)
Equity Coverage on Biotech Industry - Gilead Sciences, MannKind, ARIAD Pharma, iBio Inc., and Celgene
PR Newswire - Fri Nov 14, 8:10AM CST
Investor-Edge has initiated coverage on the following equities: Gilead Sciences Inc. (NASDAQ: GILD), MannKind Corporation (NASDAQ: MNKD), ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), iBio Inc. (NYSE MKT: IBIO), and Celgene Corporation (NASDAQ: CELG). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Thursday, November 13, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,652.79, up 0.23% and the NASDAQ Composite closed at 4,680.14, up 0.11%. The S&P 500 finished the session 0.05% higher at 2,039.33. During the trading session, four out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 783.78, down 0.10%, whereas the index has gained 10.85% in the previous three months. Register for your complimentary reports on these five stocks at:
GILD: 101.82 (+0.94), IBIO: 0.77 (-0.13), ARIA: 7.20 (-0.26), MNKD: 5.41 (-0.29), CELG: 113.63 (-0.60)
'Mad Money' Lightning Round: A Group to Avoid
at The Street - Fri Nov 14, 5:00AM CST
Cramer says he's not going against Affymetrix, and doesn't want to get back into the sand game.
DCT: 34.46 (+0.46), CBI: 46.07 (-1.33), FMSA: 8.03 (-0.64), KODK: 21.30 (+0.10), WNR: 42.58 (-0.67), FRT: 132.81 (+0.13), ARIA: 7.20 (-0.26), AFFX: 9.14 (-0.04), ADSK: 61.09 (-0.36)
Cramer's Lightning Round - Affymetrix Teased And Disappointed, But Is A Buy (11/13/14)
SA Editor Miriam Metzinger - Seeking Alpha - Fri Nov 14, 2:40AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday November 13. Bullish Calls: Affymetrix (NASDAQ: AFFX ): "This company has over time teased people and then disappointed them, but I believe...
CBI: 46.07 (-1.33), FMSA: 8.03 (-0.64), KODK: 21.30 (+0.10), WNR: 42.58 (-0.67), FRT: 132.81 (+0.13), ARIA: 7.20 (-0.26), ADSK: 61.09 (-0.36), AFFX: 9.14 (-0.04)
Jim Cramer's 'Mad Money' Recap: Market 'Losers' Back in the Game
at The Street - Thu Nov 13, 5:49PM CST
Some stocks written off by this market are looking better than ever, Cramer says.
FLEX: 11.27 (+0.03), KMB: 114.60 (-0.10), M: 62.50 (-1.16), WMT: 84.76 (-0.18), FLTX: 34.30 (-0.17), AFFX: 9.14 (-0.04), DPS: 72.12 (-0.28), DCT: 34.46 (+0.46), JACK: 75.87 (+0.42), FMSA: 8.03 (-0.64), CSCO: 27.77 (-0.18), CBI: 46.07 (-1.33), KODK: 21.30 (+0.10), DIS: 93.23 (+0.12), WNR: 42.58 (-0.67), FRT: 132.81 (+0.13), BA: 131.32 (-0.65), PLKI: 54.22 (-0.47), AZO: 588.07 (-2.48), JCP: 6.73 (-0.46), JWN: 75.70 (-0.63), ARIA: 7.20 (-0.26), DOW: 49.77 (+0.35), ADSK: 61.09 (-0.36)
ARIAD Announces Iclusig Data Presentations at Annual American Society of Hematology Meeting
Business Wire - Thu Nov 06, 8:44AM CST
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced the schedule of several data presentations on Iclusig(R) (ponatinib) that will take place at the 56th Annual Meeting of the American Society of Hematology (ASH) being held in San Francisco, December 6 to 9, 2014. A total of 17 abstracts were accepted at ASH. The schedule and meeting location for key sessions at ASH, together with the abstract information, are listed below:
ARIA: 7.20 (-0.26)
Ariad Pharmaceuticals' (ARIA) CEO Harvey Berger on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 05, 11:47AM CST
ARIA: 7.20 (-0.26)
